Envoy Medical has been granted two new international patents, increasing its global intellectual property portfolio to 97 patents, including 40 U.S. and 57 foreign patents. These patents protect innovative technologies for fully implanted hearing devices that use the ear's natural anatomy to capture sound, differentiating Envoy Medical from competitors. The new patents cover advanced cochlear system components and methods to compensate for sensor variability, supporting future product development. Envoy Medical continues clinical trials for its investigational Acclaim cochlear implant and markets the FDA-approved Esteem middle ear implant, aiming to improve hearing solutions worldwide.
Envoy Medical's recent expansion of its global patent portfolio provides context for readers following health technology innovations. For readers following the health sector, here is Pluang's market snapshot as of Sep 22, 2026 19:02 WIB: Among 101 priced US health-sector stocks, 50 rose and 41 fell. Notably, NUWE traded at USD 0.86 with a 1-day change of -1.46% and a typical hold time of 23 days, TWST was priced at USD 167.99 with a 1-day gain of +1.31% and a 28-day hold time, while GSK stood at USD 50.50, down 1.14% for the day with a 91-day hold time and 100% sell order activity on Pluang.
THOR Industries reported Q4 earnings with an EPS of $0.78, missing analyst estimates and showing a 66.9% drop from last year. Despite this, the company beat revenue expectations with $2.31 billion, though revenue declined 8.4% year-over-year due to w...
Cracker Barrel Old Country Store is set to report its Q3 2026 earnings on September 23, with analysts predicting a significant decline. Earnings per share are expected to fall to $0.17 from $0.74 last year, and revenue is forecasted around $834.57 mi...
Abivax received positive pre-NDA feedback from the U.S. FDA for its drug Obefazimod, marking a key step in its development. Despite a recent price target cut by Wedbush to $118, analysts maintain a "Moderate Buy" consensus with an average target of $...
HSBC and Wells Fargo have downgraded Netflix stock due to declining subscriber engagement and an 8% drop in viewership time. Despite a recent 2.19% stock gain, Netflix shares have fallen over 40% in the past year amid strong competition and weaker or...
A director at FormFactor sold 2,100 shares, indicating a notable insider transaction. Such sales can reflect personal financial decisions or strategic portfolio adjustments by company insiders. Investors often watch these moves for potential signals ...
